Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q3 EPS of ($0.59), $0.14 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $15.29 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.